Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LRRK1 antisense RNA 1 (LRRK1-AS1) is a long noncoding RNA expressed from the antisense strand of the LRRK1 gene. It is predominantly localized in the cytoplasm and is independently regulated from its sense counterpart. In lung squamous cell carcinoma, LRRK1-AS1 drives tumor cell proliferation through pathways including DNA replication and cell cycle progression, apparently by downregulating genes in E2F and Myc signaling pathways. Mechanistic models propose that LRRK1-AS1 either stabilizes certain proteins or acts as a microRNA sponge, sequestering them and thereby lifting their repression on mRNAs of proliferative genes (such as E2F1). Its expression is inducible by epigenetic drugs, illustrating potential links to chromatin accessibility and tumor transcriptional complexity. LRRK1-AS1 is considered a potential biomarker and therapeutic target for cancers that feature cryptic antisense transcription.
Not directly targeted by drugs; functional mechanisms proposed include: Stabilization or interaction with regulatory proteins (e.g., E2F1); Acting as an RNA sponge for microRNAs, affecting mRNA stability and translation efficiency of key proliferative genes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LRRK1 antisense RNA 1 (LRRK1-AS1).